AnaptysBio Inc ANAB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/13/24 EDT
23.99UNCH (UNCH)
Volume
80,798
Close
23.99UNCH (UNCH)
Volume
352,486
52 week range
13.36 - 27.50
Loading...
  • Open23.46
  • Day High24.70
  • Day Low23.41
  • Prev Close23.41
  • 52 Week High27.50
  • 52 Week High Date02/26/24
  • 52 Week Low13.36
  • 52 Week Low Date11/28/23

Key Stats

  • Market Cap655.374M
  • Shares Out27.32M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta-0.33
  • YTD % Change12

KEY STATS

  • Open23.46
  • Day High24.70
  • Day Low23.41
  • Prev Close23.41
  • 52 Week High27.50
  • 52 Week High Date02/26/24
  • 52 Week Low13.36
  • 52 Week Low Date11/28/23
  • Market Cap655.374M
  • Shares Out27.32M
  • 10 Day Average Volume0.46M
  • Dividend-
  • Dividend Yield-
  • Beta-0.33
  • YTD % Change12

RATIOS/PROFITABILITY

  • EPS (TTM)-6.13
  • P/E (TTM)-3.91
  • Fwd P/E (NTM)-3.74
  • EBITDA (TTM)-161.562M
  • ROE (TTM)-136.73%
  • Revenue (TTM)22.962M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-711.17%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On AnaptysBio Inc

 

Profile

MORE
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The...
John Orwin
Chairman of the Board
Daniel Faga
President, Chief Executive Officer, Director
Eric Loumeau J.D.
Chief Operating Officer, General Counsel
Dennis Mulroy CPA
Chief Financial Officer
Address
10770 WATERIDGE CIRCLE, SUITE 210
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
AUTL
Autolus Therapeutics PLC
4.01UNCHUNCH
COGT
Cogent Biosciences Inc
7.35UNCHUNCH
IRON
Disc Medicine Inc
31.01UNCHUNCH
DNTH
Dianthus Therapeutics Inc
26.01UNCHUNCH
EXAI
Exscientia PLC
4.91UNCHUNCH